key: cord-1054697-ko490awu
authors: Diamond, Michael; Halfmann, Peter; Maemura, Tadashi; Iwatsuki-Horimoto, Kiyoko; Iida, Shun; Kiso, Maki; Scheaffer, Suzanne; Darling, Tamarand; Joshi, Astha; Loeber, Samantha; Foster, Stephanie; Ying, Baoling; Whitener, Bradley; Floyd, Katharine; Ujie, Michiko; Nakajima, Noriko; Ito, Mutsumi; Wright, Ryan; Uraki, Ryuta; Li, Rong; Sakai, Yuko; Liu, Yanan; Larson, Deanna; Osorio, Jorge; Hernandez-Ortiz, Juan; Čiuoderis, Karl; Florek, Kelsey; Patel, Mit; Bateman, Allen; Odle, Abby; Wong, Lok-Yin; Wang, Zhongde; Edara, Venkata Viswanadh; Chong, Zhenlu; Thackray, Larissa; Ueki, Hiroshi; Yamayoshi, Seiya; Imai, Masaki; Perlman, Stanley; Webby, Richard; Seder, Robert; Suthar, Mehul; Garcia-Sastre, Adolfo; Schotsaert, Michael; Suzuki, Tadaki; Boon, Adrianus; Kawaoka, Yoshihiro; Douek, Daniel; Moliva, Juan; Sullivan, Nancy; Gagne, Matthew; Ransier, Amy; Case, James; Jeevan, Trushar; Franks, John; Fabrizio, Thomas; DeBeauchamp, Jennifer; Kercher, Lisa; Seiler, Patrick; Singh, Gagandeep; Warang, Prajakta; Gonzalez-Reiche, Ana S.; Sordillo, Emilia; van Bakel, Harm; Simon, Viviana
title: The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters
date: 2021-12-29
journal: Res Sq
DOI: 10.21203/rs.3.rs-1211792/v1
sha: b8cb818450df2d8001b5fe6a8708e21720e4bfd3
doc_id: 1054697
cord_uid: ko490awu

Despite the development and deployment of antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. The recent emergence of B.1.1.529, the Omicron variant1,2, which has more than 30 mutations in the spike protein, has raised concerns for escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in pre-clinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) program of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of multiple B.1.1.529 Omicron isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2) expressing mice and hamsters. Despite modeling and binding data suggesting that B.1.1.529 spike can bind more avidly to murine ACE2, we observed attenuation of infection in 129, C57BL/6, and BALB/c mice as compared with previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. Although K18-hACE2 transgenic mice sustained infection in the lungs, these animals did not lose weight. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease, and pathology with B.1.1.529 also were milder compared to historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from multiple independent laboratories of the SAVE/NIAID network with several different B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global Coronavirus Disease 2019 (COVID-19) pandemic resulting in millions of deaths worldwide. The extensive morbidity and mortality associated with the COVID-19 pandemic made the development of SARS-CoV-2 vaccines, antibody-based countermeasures, and direct acting antiviral agents a global health priority. As part of the development process, several key animal models of SARS-CoV-2 infection and lung pathogenesis were developed in mice, hamsters, nonhuman primates (NHP) and other animals for rapid testing and evaluation 3 . Remarkably, several highly effective vaccines and antibody therapeutics targeting SARS-CoV-2 spike protein gained regulatory approval and were deployed with hundreds of millions of doses given worldwide (https://covid19.who.int). While these measures markedly reduced numbers of infections, hospitalizations, and deaths, their e cacy has been jeopardized by emergence of highly transmissible variant SARS-CoV-2 strains with mutations in the spike protein that could compromise protective immune responses and therapeutics.

Currently available vaccines and antibody countermeasures were developed using the SARS-CoV-2 spike protein from strains circulating during the early phases of the pandemic in 2020. The SARS-CoV-2 spike protein engages angiotensin-converting enzyme 2 (ACE2) on the surface of human cells to facilitate entry and infection of cells 4 . Upon cell attachment, SARS-CoV-2 spike proteins are cleaved by host proteases into S1 and S2 fragments. The S1 protein includes the N-terminal (NTD) and receptor binding (RBD) domains, whereas the S2 protein promotes membrane fusion. The RBD, in particular, is the target of many potently neutralizing monoclonal [5] [6] [7] [8] [9] (mAb) and serum polyclonal antibodies 10 . Although SARS-CoV-2 spike proteins from strains early in the pandemic bound to ACE2 from multiple susceptible animal species (e.g., hamster, ferret, and NHP), they did not bind mouse ACE2, which explained why conventional laboratory strains of mice could not be infected e ciently by SARS-CoV-2 4, 11 ; indeed, mice could become susceptible through ectopic expression of hACE2 via a transgene [12] [13] [14] , adenoviral vector delivery 15, 16 , or expression of hACE2 by the mouse ACE2 promoter [17] [18] [19] . However, later in the pandemic, several variant strains (e.g., B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28 (Gamma), and B.1.621 (Mu)) acquired a mouse-adapting spike mutation (N501Y), which allowed engagement of murine ACE2 and productive infection of laboratory strains of mice without ectopic hACE2 expression [20] [21] [22] .

In late November of 2021, the Omicron (B.1.1.529) variant emerged, which has the largest number (>30) of mutations, deletions, or insertions in the spike protein described to date. This number of changes in the spike has raised concerns for escape from protection by vaccines and therapeutic mAbs. Most B.1.1.529 isolates have a constellation of changes in the spike protein including: A67V, D69-70, T95I, G142D, D143-145, D211, L212I, insertion 214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F. The presence of the N501Y mutation along with additional mutations (K417, E484, Q493, Q498, and N501) at sites associated with mouse adaptation by serial passage [23] [24] [25] [26] [27] [28] suggested that B.1.1.529 should infect laboratory strains of mice 29 . Indeed, one recent study speculated that because mutations in the B.1.1.529 spike protein overlap with ones known to promote adaptation to mouse hosts, the progenitor of B.1.1.529 jumped from humans to mice, and then back into humans 30 . In support of this, B.1.1.529 but not Wuhan-1 RBD binds to murine ACE2 31 . Lastly, hamsters have been a valuable pre-clinical animal model for assessing countermeasures against SARS-CoV2 and variants. Hamsters are highly susceptible to SARS-CoV-2 infection with similar pathological changes seen in lung tissues from COVID-19 patients 3,32,33 . Here, using experimental data from multiple laboratories of the SAVE/NIAID consortium, we report on the infectivity of multiple B. substitution (e.g. WA1/2020 N501Y/D614G or B.1.351), 129 mice sustain 10 to 15% loss of body weight. However, after inoculation of B.1.1.529, 129 mice failed to lose weight in all three laboratories (Fig 1a) . Similarly, aged (10 to 14-month-old) C57BL/6 breeders also did not lose signi cant weight after B.1.1.529 infection, whereas those infected with B.1.351 did (Fig 1a) . We next measured the viral burden in the upper and lower respiratory tract of B.1.1.529-infected 129 mice and compared this to side-by-side infection with B.1.351 or historical data with WA1/2020 N501Y/D614G 22, 34 . At 3 or 4 dpi, 129 mice infected with WA1/2020 N501Y/D614G or B.1.351 sustained high levels of infection in the nasal wash, nasal turbinates, and lungs (Fig 1b-c) ; this level of infection previously was associated with histological evidence of mild pneumonia 20, 22, 34 . At 3 dpi, B.1.1.529 infection in the nasal turbinates and lungs was 10 to 100-fold lower than in B.1.351-infected mice (P < 0.01, Fig 1c) . At 4 dpi, in contrast to WA1/2020 N501Y/D614G infection, we were unable to detect B.1.1.529 viral RNA in the nasal wash. Moreover, at this time point, 10 to 100-fold lower levels of viral RNA were present in lung homogenates of B.1.1.529-infected mice compared to WA1/2020 N501Y/D614G-infected mice (Fig 1b) . (Fig 1d) . We next used a whole-body plethysmography system 35 14 . At intranasal inoculating doses ranging from 10 3 to 10 5 infectious units of B.1.1.529, weight loss was not observed over the rst 5 to 6 days of infection in younger or older K18-hACE2 mice (Fig 1f) . These data contrasts with historical results with WA1/2020 D614G or variant (e.g., B.1.351) SARS-CoV-2 strains 14, 22, 34, 36 , which uniformly induce weight loss starting at 4 dpi. Although we observed clinical attenuation of B.1.1.529 in K18-hACE2 mice, the virus nonetheless accumulated in the upper and lower respiratory tract (Fig 1g) . CoV-2 strains generally resulted in ~10 to 15% reduction in body weight over the rst week, we observed no weight loss in any of the hamsters inoculated with B.1.1.529, regardless of inoculating dose (Fig 2a-e) . However, animals infected with B.1.1.529 did not gain body weight as rapidly as uninfected hamsters. Viral RNA analysis at 4 dpi showed lower levels of B.1.1.529 infection in the nasal wash (2-fold, P < 0.05) and lungs (12-fold, P < 0.001) compared to WA1/2020 D614G ([A.C.M.B.]; Fig 2f) . A comparison of infectious viral burden in tissues at 3 dpi between B.1.617.2 (Delta) and B.1.1.529 (Omicron) viruses [Y.K.] showed virtually no difference in nasal turbinates but substantially less infection of B.1.1.529 in the lungs of most animals (Fig 2g) . A comparison of viral RNA levels between WA1/2020 and B.1.1.529 viruses (R.J.W) in nasal washes at 4 dpi did not show substantial differences in nasal wash titers (Fig  2h) . Thus, in hamsters, upper, but not lower, respiratory tract infection by B.1.1.529 appears relatively intact.

We also used whole-body plethysmography to measure pulmonary function in infected Syrian hamsters We next performed microcomputed tomography (micro-CT) to assess for lung abnormalities in hamsters at 7 dpi. We used a previously de ned CT severity score (see Legend and Methods) to evaluate animals for nodules, ground glass opacities, and regions of lung consolidation 35 . Micro-CT analysis revealed lung abnormalities in all B.1.617.2-infected hamsters on 7 dpi that were consistent with commonly reported imaging features of COVID-19 pneumonia 37 . In comparison, analysis of B.1.1.529-infected hamsters on 7 dpi revealed patchy, ill-de ned ground glass opacity consistent with minimal to mild pneumonia. Accordingly, Syrian hamsters infected with B.1.617.2 had a high CT disease score (~12), whereas those infected with B.1.1.529 had a substantially lower disease score (~2) that was only slightly greater than mock-infected hamsters (Fig 2j-k) .

We also compared lung pathology in Syrian hamsters after infection with B.1.617.2 or B.1.1.529 viruses.

Macroscopically, the lungs obtained from the B.1.617.2-infected hamsters showed congestion and/or hemorrhage, but this was absent in B.1.1.529-infected animals ( Fig. 3a) . At the microscopic level, immune cell in ltration and in ammation were present in the peribronchial regions of the lungs at 3 dpi with B.1.617.2. Moreover, at 6 days post B.1.617.2 infection, extensive in ltration of neutrophils and lymphocytes in the alveolar space and walls was accompanied by focal pulmonary edema and alveolar hemorrhage (Fig 3b, inset) , and regenerative changes in the bronchial epithelia became prominent (Fig  3b) . In contrast, in B.1.1.529-infected hamsters, small foci of in ammation in the alveoli and peribronchial regions were observed only at 6 dpi (Fig 3b) . A semi-quantitative histopathology severity score of viral pneumonia at 6 dpi showed a worse score after B.1.617.2 than B.1.1.529 infection (Fig 3c) .

Consistent with these ndings, after B.1.617.2 infection, viral RNA was detected readily in the alveoli and bronchial epithelia in lung tissue sections at 3 and 6 dpi (Fig 3d) . In comparison, after B.1.1.529 infection, fewer bronchial epithelial cells and alveoli were positive for viral RNA at either time point (Fig 3d) . Collectively, these ndings suggest that the B.1.1.529 Omicron variant replicates less e ciently in the lungs of Syrian hamsters, which results in less severe pneumonia compared to the B.1.617.2 Delta variant.

Although hamsters are susceptible to SARS-CoV-2 infection without a requirement for host adaptation and show some similarities to that observed in COVID-19 patients, they develop self-limiting clinical and respiratory disease. Even though hamster ACE2 can serve as a receptor for SARS-CoV-2 spike protein, some of the contact residues in human ACE2 are not conserved 38 , which could diminish infectivity. Moreover, ACE2 expression levels on particular cells in the respiratory tract may differ slightly between hamsters and humans, which could impact infectivity and clinical outcome. To develop a more susceptible hamster model, members of the consortium (Y.K.) used transgenic hamsters (generated by Z.W.) expressing human ACE2 under the epithelial cytokeratin-18 promoter 39 . Whereas intranasal inoculation of 10 3 PFU of HP-095 D614G virus resulted in marked weight loss within the rst week (Fig 2l) and uniform mortality by 10 dpi (Fig 2m) , less weight loss and death (P < 0.05) were observed after infection with 10 3 PFU of B.1.1.529. Consistent with these clinical data, 1,000 to 10,000-fold lower levels of infectious virus were measured in the lungs of hACE2 transgenic hamsters challenged with B.1.1.529 compared to the HP-095 D614G virus at 3 and 5 dpi (Fig 2n) . Notably, and as seen in wild-type Syrian hamsters, smaller differences in infection were observed in the nasal turbinates. Thus, B.1.1.529 infection in the lung is attenuated in both wild-type and hACE2 transgenic hamsters.

Our experiments suggest that compared to other SARS-CoV-2 isolates (e.g., B.1.351 or B.1.617.2), the B.1.1.529 Omicron variant infection is attenuated in laboratory mice and hamsters for causing infection and/or disease. While these results are consistent with the very preliminary clinical data in humans suggesting that B.1.1.529 causes a more transmissible yet possibly milder respiratory infection 40, 41 , the basis for the attenuation in rodents remains unknown. One pre-print study suggests that B.1.1.529 replicates faster in the human bronchus and less in lung cells, which may explain its greater transmissibility and putative lower disease severity 42 ; although it remains unclear if these observations extend to rodents, we observed less infection of hamster bronchial cells in vivo with B.1.1.529 Omicron than B.1.617.2 Delta virus. We also measured lower viral burden in nasal washes and turbinates in 129 mice compared to other SARS-CoV-2 strains. The attenuation in mice was unexpected given that B.1.1.529 has multiple mutations in the RBD that are sites (K417, E484, Q493, Q498, and N501) associated with adaptation for mice [23] [24] [25] . Moreover, the attenuation in hamsters also was surprising, given that all prior SARS-CoV-2 variants have replicated relatively equivalently and to high levels in this animal 35, 43, 44 . However, our results showing attenuation of B.1.1.529 in hamsters are consistent with another preliminary report 45 . Whereas the more than 30 substitutions (mutations, deletions, and Page 11/27 insertions) in the B.1.1.529 could impact receptor engagement and cell entry, sequence changes in other structural, non-structural, and immune evasion proteins could affects replication, temperature sensitivity, cell-to-cell spread, cell and tissue tropism, dissemination, and induction of pro-in ammatory immune responses in a species-speci c manner. Thus, detailed genetic and functional studies are required to de ne the basis of virological and clinical attenuation of B.1.1.529 in mice and hamsters.

Although we observed clinical attenuation of B.1.1.529 in mice and hamsters, these animals likely will still have utility in evaluating vaccine, antibody, or small molecule inhibitors. All of the mice and hamsters tested, to varying degrees, showed evidence of viral replication and dissemination to the lower respiratory tract, which could be prevented or mitigated by prophylactic or therapeutic countermeasures. The most severe B.1.1.529 infection and disease was observed in hACE2 expressing mice and hamsters, which is consistent with results with other SARS-CoV-2 strains and variants 14, 22, 39, 46 Hamster infection experiments. Five-to-six-week-old male hamsters were obtained from Charles River Laboratories, Envigo, or Japan SLC Inc. The K18-hACE2 transgenic hamster line was developed with a piggyBac-mediated transgenic approach, in which the K18-hACE2 cassette from the pK18-hACE2 plasmid 12 was transferred into a piggyBac vector, pmhyGENIE-3 54 , for pronuclear injection. hACE2 transgenic hamsters will be described in detail elsewhere 39 ] Lungs were collected 4 dpi and homogenized in 1.0 mL DMEM, clari ed by centrifugation (1,000 x g for 5 min) and stored at -80°C. Nasal washes were clari ed by centrifugation (2,000 x g for 10 min) and the supernatant was stored at -80°C. To quantify viral load in lung tissue homogenates and nasal washes, RNA was extracted from 100 µL samples using E.Z.N.A. ® Total RNA Kit I (Omega) and eluted with 50 µL of water. Four microliters RNA was used for real-time RT-qPCR to detect and quantify N gene of SARS-CoV-2 using TaqMan™ RNA-to-CT 1-Step Kit (Thermo Fisher Scienti c) as described 57 . [Y.K.] The virus titers in the nasal turbinates and lungs were determined by plaque assay on Vero E6 cells expressing human TMRPSS2 as previously published 58 . [R.J.W.] RNA was extracted from clari ed nasal washes using the Qiagen RNeasy extraction kit (Qiagen, Hilden Germany) following the manufacturer's instructions. Samples were puri ed on the included columns and eluted in 50 µL of nuclease free water. PCR was conducted using 4X TaqMan Fast Virus Master Mix (Thermo Fisher) and the HKU N-gene primer/probe set.

Plaque assay. Vero-TMPRSS2 or Vero-TMPRSS2-hACE2 cells were seeded at a density of 1×10 5 cells per well in 24-well tissue culture plates. The following day, medium was removed and replaced with 200 μL of material to be titrated diluted serially in DMEM supplemented with 2% FBS. One hour later, 1 mL of methylcellulose overlay was added. Plates were incubated for 72 h, then xed with 4% paraformaldehyde A CT severity score, adapted from a human scoring system, was used to grade the severity of the lung abnormalities 59 . Each lung lobe was analyzed for degree of involvement and scored from 0-4 depending on the severity: 0 (none, 0%), 1 (minimal, 1%-25%), 2 (mild, 26%-50%), 3 (moderate, 51%-75%), or 4 (severe, 76%-100%). Scores for the ve lung lobes were summed to obtain a total severity score of 0-20, re ecting the severity of abnormalities across the three infected groups. Images were anonymized and randomized; the scorer was blinded to the group allocation.

Pathology. Excised animal tissues were xed in 4% paraformaldehyde in PBS, and processed for para n embedding. The para n blocks were cut into 3-µm-thick sections and mounted on silane-coated glass slides. Sections were processed for in situ hybridization using an RNA scope 2.5 HD Red Detection kit (Advanced Cell Diagnostics, Newark, California) with antisense probe targeting the nucleocapsid gene of SARS-CoV-2 (Advanced Cell Diagnostics). Speci c antigen-antibody reactions were visualized by means of 3,3'-diaminobenzidine tetrahydrochloride staining using the Dako Envision system (Dako Cytomation).

Lung tissue sections also were scored based on pathological changes. Scores were determined based on the percentage of alveolar in ammation in a given area of a pulmonary section collected from each animal in each group by using the following scoring system: 0, no pathological change; 1, affected area (≤10%); 2, affected area (<50%, >10%); 3, affected area (≥50%); an additional point was added when pulmonary edema and/or alveolar hemorrhage was observed.

Data availability. All data supporting the ndings of this study are available within the paper, in the Source Data, and from the corresponding author upon request. There are no restrictions in obtaining access to primary data.

Code availability. No code was used in the course of the data acquisition or analysis. 

How bad is Omicron? What scientists know so far

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

Animal models for COVID-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent neutralizing antibodies against SARS-CoV-2 identi ed by high-throughput single-cell sequencing of convalescent patients' B cells

Rapid isolation and pro ling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung in ammation and impaired function

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv : the preprint server for health sciences

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine e cacy

In vivo monoclonal antibody e cacy against SARS-CoV-2 variant strains

Intranasal immunization with a vaccinia virus vaccine vector expressing prefusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y<sub>MA30</sub> strain of SARS-CoV-2. bioRxiv

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19. bioRxiv

CCR2 Signaling Restricts SARS-CoV-2 Infection

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

<em>But Mouse, you are not alone</em>: On some severe acute respiratory syndrome coronavirus 2 variants infecting mice. bioRxiv

Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. bioRxiv

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

American College of Radiology, and RSNA -Secondary Publication

Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates

Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. bioRxiv

Epidemiological characterisation of the rst 785 SARS-CoV-2 Omicron variant cases in Denmark

How bad is Omicron? Some clues are emerging

Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model

Enhanced tness of SARS-CoV-2 variant of concern Alpha but not Beta

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. bioRxiv

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serumderived polyclonal antibodies

Spike mutation D614G alters SARS-CoV-2 tness

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Generation of transgenic pigs by cytoplasmic injection of piggyBac transposase-based pmGENIE-3 plasmids

Growth, detection, quanti cation, and inactivation of SARS-CoV-2

CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infection. bioRxiv

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

SARS-CoV-2 Interference of In uenza Virus Replication in Syrian Hamsters

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Center right: Weight change in 129 mice inoculated intranasally with 10 6 PFU of B.1.1.529 (strain hCoV19/EHC_C19_2811C, green circles, n = 5) or B.1.351 (black triangles

or B.1.351 (black squares, n = 18). Data are mean ± SEM. b, Nasal wash and lung viral RNA levels in 129 mice

Nasal turbinates and lung virus titers from BALB/c mice inoculated with 10 5 PFU of B.1.1.529 (strain hCoV-19/Japan/NC928-2N/2021, blue circles, n = 5) or B.1.351 (black squares, n = 5) (** P < 0.001, by Mann-Whitney U test). e, Pulmonary function analysis in infected BALB/c mice. Penh, a surrogate marker for bronchoconstriction or airway obstruction, was measured by whole body plethysmography. Data are presented as the mean ± SEM. P values were calculated by using pairwise comparisons after a linear mixed model analysis (***P < 0.001)

Data are mean ± SEM. c, Weight change in uninfected age-matched Syrian hamsters (open grey circles, n = 9) or in hamsters inoculated intranasally with 10 3 PFU of B.1.1.529 (strain hCoV-19/USA/WI-WSLH-221686/2021, red circles, n = 10) or WA1/2020 D614G (black triangles, n = 6). Data are mean ± SEM

Data are mean ± SEM. f, Nasal wash and lung viral RNA load in wild-type Syrian hamsters inoculated with 10 3 PFU of WA1/2020 D614G (black triangles, n = 15) or B.1.1.529 (strain hCoV-19/USA/WI-WSLH-221686/2021, red circles, n = 15) (*** P < 0.001, * P < 0.05 by unpaired t-test). g, Nasal turbinates and lung virus titer in wildtype Syrian hamsters inoculated with 10 3 PFU of B.1.617.2 (strain

Asterisks indicate statistically signi cant differences between B.1.617.2-infected (n = 4) and B.1.1.529-infected (n = 4) or uninfected animals (n = 3). j, Representative micro-CT axial and coronal images of the lungs of mock-infected (n = 3) or B.1.617.2-(n = 4) and B.1.1.529-infected (n = 4) hamsters on 7 dpi. Lung abnormalities included multifocal nodules (black arrows), ground glass opacity (white arrowheads), and regions of lung consolidation (white arrows) that were peripheral, bilateral, and multilobar. Pneumomediastinum is indicated with white asterisks. k, CT score for uninfected hamsters (open grey circles, n = 3) or those inoculated with 10 3 PFU of B.1.617.2 (black squares, n = 4) or B.1.1.529 (strain hCoV-19/Japan/NC928-2N/2021, red circles, n = 4). l, Weight change in hACE2-transgenic Syrian hamsters

The results in the Figure are from one (a, b, d-e, and g-n) or two to three independent (c, and f) experimentseach group using the following scoring: 0, no pathological change; 1, affected area (≤10%)

05. d, RNA in situ hybridization (RNA-ISH) for SARS-CoV-2 viral RNA. Representative RNA-ISH images for the alveoli and bronchi of hamsters infected with B

virus at 3 or 6 dpi are shown. Left panels, alveolar region. Right panels, bronchial region. Scale bars